EXEL : Analysis & Opinions

  1. Is Exelixis Under-the-Radar Growth?

    March 6, 2015
    Exelixis was the worst-performing biotech company, with its shares collapsing after its COMET-1 study showed that  its cancer ...
  2. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  3. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  4. Four Healthcare Stocks On Fire

    November 18, 2009
    Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...
Trading Center